Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 12/20 | 1.00 |
| ▸ | ESR1 | P03372 | 12/20 | 1.00 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14176451 | 0.85 | ESR2 (0.74) | ESR2ESR1 | |
| SCHEMBL5128209 | 0.85 | ESR2 (1.00) | ESR2ESR1MAPK1 | |
| SCHEMBL5112589 | 0.83 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL14176454 | 0.83 | ESR2 (0.71) | ESR2ESR1 | |
| SCHEMBL5112889 | 0.82 | ESR2 (1.00) | ESR2ESR1 | |
| SCHEMBL5129674 | 0.80 | ESR2 (1.00) | ESR2ESR1MAPK1 | |
| SCHEMBL5118243 | 0.79 | ESR2 (0.76) | ESR2ESR1MAPK1 | |
| SCHEMBL5117321 | 0.78 | ESR2 (1.00) | ESR2ESR1MAPK1 | |
| SCHEMBL29110427 | 0.76 | POLB (0.73) | ESR2ESR1POLBHSD17B10MAPK1 | |
| SCHEMBL30089869 | 0.76 | POLB (0.73) | ESR2ESR1POLBHSD17B10MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-7381730-B2 | 3-arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-06-03 | — | — | US | disclosed |
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220227-A1 | 3-Arylquinazoline derivatives as selective estrogen receptor beta modulators | ESR2, ESRRA, ESRRG | ESR2 1/4885ESR1 9/4885POLB 2207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.